LETTER
Cost-effectiveness of Combined Statin-Resin Therapy
David L. Katz, MD, MPH
1 October 1994 | Volume 121 Issue 7 | Pages 548-549
TO THE EDITOR:
There is a surprising omission in the study by Sprecher and colleagues [1]. Although the authors reported the lipid-lowering efficacy of various combinations of fluvastatin and cholestyramine, they made no mention of their relative costs. In clinical practice, cost-effectiveness is an increasing priority.
Sponsorship of the study by a pharmaceutical company may have been responsible for the omission. I ask that the cost-effectiveness of the drug combinations be reported.
1. Sprecher DL, Abrams J, Allen JW, Keane WF, Chrysant SG, Ginsberg H, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med. 1994; 120:537-43.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Top
References
Article
